Fairvalue-Calculator Fairvalue-Calculator
EN DE

Aligned Genetics, Inc (238120) Fair Value & Analysis

Healthcare · KR · Market cap 45.0B KRW

Price3,025 KRW
Fair Value2,183 KRW
Upside-27.8%
Quality95/100
Evidence: Medium Range 1,795 KRW – 2,472 KRW

Fair value as of: Jun 24, 2026

Analysis

Aligned Genetics, Inc (238120) currently trades at 3,025 KRW, while our model-based Fair Value estimate is 2,183 KRW — implying the stock looks roughly 27.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -95% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Aligned Genetics, Inc (238120) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2,183 KRW versus a price of 3,025 KRW — about −28% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 238120?
Our 21-model fair value for Aligned Genetics, Inc is 2,183 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 3,025 KRW.
What is the quality score of 238120?
Aligned Genetics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.